Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%
Get Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.15, $0.08 better than the analyst estimate of $0.07. Revenue for the quarter came in at $65.5 million versus the consensus estimate of $67.11 million.
EXPAREL net product revenues were $63.8 million in the first quarter of 2016, compared to $56.0 million in the first quarter of 2015.
Pacira Pharma reaffirmed FY2016 guidance.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
- Towne Bank (TOWN) Reports In-Line Q1 EPS
- ChampionX (CHX) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!